Bayer's Classon steps up to strategy role
This article was originally published in Clinica
Bayer's diagnostics division head Rolf Classon has been appointed to the new post of group healthcare strategy and business development head. The new position is part of the group's restructuring, which will see the creation of a new holding company and four operational units, including healthcare (see Clinica No 1000, p 21).
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.